![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » SIGA Announces Lead Smallpox Drug Begins Preclinical Development
SIGA Announces Lead Smallpox Drug Begins Preclinical Development
SIGA Technologies has announced that its smallpox drug, SIGA-246, has entered preclinical development.
Based on an emerging understanding of the mechanism of action and protective efficacy in four different murine (mouse) challenge models, SIGA-246 has progressed to preclinical lead status. SIGA has initiated investigational new drug application-enabling scale-up synthesis, formulation, pharmacology and toxicology studies on the drug to allow primate efficacy and human safety studies to be performed later this year.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
11Jul
-
18Jul
-
21Oct